Keywords: enzyme, Manufacturing plant investment, Myozyme, Lumizyme

Genzyme to invest 250 million euros for Belgian plant to support growth of Myozyme and Lumizyme

Article | 21 January 2011

Print This

US rare disease drug specialist Genzyme (Nasdaq: GENZ), the subject of a hostile takeover offer from France’s Sanofi-Aventis, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in